M

MiCo BioMed Co Ltd
KOSDAQ:214610

Watchlist Manager
MiCo BioMed Co Ltd
KOSDAQ:214610
Watchlist
Price: 2 290 KRW -2.35% Market Closed
Market Cap: ₩19.2B

Wall St Price Targets

Price Targets Summary
MiCo BioMed Co Ltd

There are no price targets for MiCo BioMed Co Ltd.
Lowest Forecast
Price Target
Not Available
Average Forecast
Price Target
Not Available
Highest Forecast
Price Target
Not Available
MiCo BioMed Co Ltd Competitors:
Price Targets

Revenue
Forecast

18% / Year
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
18% / Year
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
Revenue Forecast
is not available for MiCo BioMed Co Ltd

Gross Profit
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
Gross Profit Forecast
is not available for MiCo BioMed Co Ltd

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
Operating Income Forecast
is not available for MiCo BioMed Co Ltd

Pre-Tax Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
Pre-Tax Income Forecast
is not available for MiCo BioMed Co Ltd

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
Net Income Forecast
is not available for MiCo BioMed Co Ltd
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is MiCo BioMed Co Ltd's stock price target?
Not Available

MiCo BioMed Co Ltd does not have any price targets made by Wall Street professionals.

Back to Top